ArticleDigestive diseases and sciences2026
The Predictive Value of the EGGIM Score for Extensive and Incomplete Gastric Intestinal Metaplasia: Implications for Biopsy Reduction in Endoscopic Practice.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric intestinal metaplasia (IM) is a precancerous lesion, with high-risk IM (i.e., extensive or incomplete types) posing the most significant risk for gastric cancer. The endoscopic grading of gastric intestinal metaplasia (EGGIM) was developed to predict the presence of IM; however, validation studies in Asian populations are limited. This study aimed to evaluate the performance of the EGGIM in predicting IM and high-risk IM among Vietnamese patients with upper gastrointestinal symptoms.
methodsIn this cross-sectional study, patients underwent upper gastrointestinal endoscopy with IM assessment using the EGGIM score. All patients received systematic biopsies for histopathological evaluation. IM was classified as extensive if it was present in both the antrum and corpus. The IM subtype was determined using Alcian Blue and periodic acid-Schiff (PAS) staining. The predictive performance of the EGGIM for IM and high-risk IM was evaluated using the area under the receiver operating characteristic curve (AUC).
resultsA total of 295 patients were included, with a median age of 51 years and a male-to-female ratio of 1:2. The prevalence of IM was 37.3%, with 18.0% having high-risk IM (10.5% extensive and 13.9% incomplete). The EGGIM score demonstrated good predictive accuracy for IM (AUC = 0.87, 95% CI: 0.82-0.92, cutoff ≥ 1) and for high-risk IM (AUC = 0.92, 95% CI: 0.87-0.97, cutoff ≥ 5).
conclusionThe EGGIM score accurately predicts both IM and high-risk IM. It may serve as a practical, noninvasive tool to guide biopsy decisions and identify patients at elevated risk of gastric cancer.
Indexed as
Identifiers
41483436What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.